The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Ruxolitinib Phosphate (Brand name: Jakafi)
- Manufactured by
FDA-approved indication: Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
National Library of Medicine Drug Information PortalMedline Plus Health Information